Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

Topics: 

Citation
Mosenzon O, et al. The Lancet Diabetes Endocrinol 2019;7;8: 606-617.